Gabapentin
Product Images NDC 45865-995

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 45865-995). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (995)

Gabapentin Tablets 800 mg label by Medsource Pharmaceuticals, generic for Neurontin. The label shows white oval film-coated tablets, with dosage instructions indicating to take a specified number of tablets daily. Includes warning about dizziness or drowsiness and avoiding alcohol. Package quantity appears to be 90 tablets. NDC 45865-995-90.*

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

A pharmacokinetic formula panel showing the calculation for creatinine clearance (CLCr) based on age, weight, and serum creatinine, with an adjustment factor for female patients. The equation adjusts dosage consideration for Gabapentin by estimating kidney function.*

FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of gabapentin showing a cyclohexane ring with attached amino methyl (CH2NH2) and acetic acid (CH2CO2H) groups.*

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph displaying mean pain scores over an 8-week period comparing Placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks including baseline, and the y-axis shows mean pain scores from 0 to 10. The graph marks a 4-week dose titration period followed by a 4-week fixed dose period, showing a decline in pain scores for Gabapentin compared to a stable level for Placebo.*

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

Line chart comparing mean pain scores over 7 weeks among patients receiving placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks from baseline through a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores. Both Gabapentin doses show a greater reduction in pain scores over time compared to placebo.*

FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares response rates between placebo (PBO) and Gabapentin (GBP) doses in two studies, showing percentages of responders for PBO and various GBP doses (3600 mg in Study 1; 1800 mg and 2400 mg in Study 2). Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing differences (%) by daily dose (mg) for Gabapentin across three studies labeled a, b, and c. The x-axis shows daily doses from 600 to 1800 mg, and the y-axis shows difference percentages from 2 to 22%. Data points for each study are plotted at 600, 900, 1200, and 1800 mg doses, showing variance trends between studies.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.